Lanreotide acetate (DrugBank: Lanreotide, Acetate)
43 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
1 | 球脊髄性筋萎縮症 | 0 |
2 | 筋萎縮性側索硬化症 | 0 |
6 | パーキンソン病 | 0 |
10 | シャルコー・マリー・トゥース病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
35 | 天疱瘡 | 0 |
40 | 高安動脈炎 | 0 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 0 |
51 | 全身性強皮症 | 0 |
60 | 再生不良性貧血 | 0 |
64 | 血栓性血小板減少性紫斑病 | 0 |
67 | 多発性嚢胞腎 | 1 |
70 | 広範脊柱管狭窄症 | 0 |
71 | 特発性大腿骨頭壊死症 | 0 |
73 | 下垂体性TSH分泌亢進症 | 1 |
75 | クッシング病 | 0 |
76 | 下垂体性ゴナドトロピン分泌亢進症 | 0 |
78 | 下垂体前葉機能低下症 | 0 |
79 | 家族性高コレステロール血症(ホモ接合体) | 0 |
81 | 先天性副腎皮質酵素欠損症 | 0 |
83 | アジソン病 | 0 |
85 | 特発性間質性肺炎 | 1 |
86 | 肺動脈性肺高血圧症 | 0 |
88 | 慢性血栓塞栓性肺高血圧症 | 0 |
90 | 網膜色素変性症 | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
113 | 筋ジストロフィー | 0 |
145 | ウエスト症候群 | 0 |
156 | レット症候群 | 0 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 0 |
171 | ウィルソン病 | 0 |
206 | 脆弱X症候群 | 0 |
222 | 一次性ネフローゼ症候群 | 0 |
224 | 紫斑病性腎炎 | 0 |
225 | 先天性腎性尿崩症 | 0 |
227 | オスラー病 | 0 |
235 | 副甲状腺機能低下症 | 0 |
265 | 脂肪萎縮症 | 0 |
288 | 自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)] | 0 |
298 | 遺伝性膵炎 | 1 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2011-005017-37-NL (EUCTR) | 30/05/2012 | 21/05/2012 | To investigate the effect of Lanreotide on renal function decline in ADPKD patients | A randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study | First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume. MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Somatuline Autogel Product Name: Lanreotide Product Code: BIM 23014 INN or Proposed INN: Lanreotide Other descriptive name: LANREOTIDE ACETATE | DIPAK Consortium | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-JapicCTI-173772 | 22/1/2018 | 15/11/2017 | Phase 3 Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma | Phase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma | TSH-secreting pituitary adenoma | Intervention name : Lanreotide Acetate INN of the intervention : Lanreotide Dosage And administration of the intervention : Deep subcutaneous administration of 60 mg, 90 mg or 120 mg of lanreotide once every 4 weeks. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | TEIJIN PHARMA LIMITED | NULL | complete | 20 | BOTH | 8 | Phase 3 | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2011-003687-78-IT (EUCTR) | 21/02/2012 | 05/03/2012 | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) - IPF/LANREOTIDE/2011-01 | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | INN or Proposed INN: LANREOTIDE ACETATE Product Name: Gallium68-Dota-Noc Product Code: NA INN or Proposed INN: NA Other descriptive name: NA | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2009-016082-29-BE (EUCTR) | 10/03/2010 | 25/11/2009 | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Paraduodenal pancreatitis MedDRA version: 12.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis | Trade Name: Somatuline Autogel 90 mg Other descriptive name: LANREOTIDE ACETATE | Erasme hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Belgium |